Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease
Signifies the FDA’s recognition of the Company’s novel Cognitive Behavioral Therapy as a potential treatment for metabolic dysfunction-associated steatohepatitis Opens an accelerated path...
United States Frank Karbe Naim Alkhouri Drug Administration Steatotic Liver Program At Arizona Health Exchange Commission
Source: marketscreener.com